PMID- 36034824
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220830
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Efficacy and Safety of Apatinib for the Treatment of Advanced or Recurrent 
      Cervical Cancer: A Single-Arm Meta-Analysis Among Chinese Patients.
PG  - 843905
LID - 10.3389/fphar.2022.843905 [doi]
LID - 843905
AB  - Background: Although various effective compounds for the second- and third-line 
      treatment of advanced or recurrent cervical cancer improved the overall survival, 
      the optimal regimen remains controversial. Previous studies revealed that 
      apatinib had extensive anti-tumor activities. However, almost all studies on 
      apatinib in recurrent cervical cancer are non-randomized controlled trials with 
      small sample sizes, different first-line treatments, and uncontrolled statistical 
      analysis, which may result in a lack of effective metrics to evaluate the 
      efficacy and safety of apatinib. Here, this meta-analysis aims to evaluate the 
      efficacy and safety of apatinib in patients with advanced or recurrent cervical 
      cancer. Methods: PubMed, Embase, the Cochrane Library, and Web of Science 
      databases were systematically searched for relevant studies. Outcomes including 
      overall response rate (ORR), disease control rate (DCR), progression-free 
      survival (PFS), overall survival (OS), and adverse events (AEs) were extracted 
      for further analysis. Results: Seven studies involving 243 patients were enrolled 
      in this meta-analysis. In terms of tumor response, the pooled ORR and DCR were 
      22.9% and 68.6%, respectively. With regard to survival analysis, the pooled PFS 
      and OS were 5.19 months and 10.63 months, respectively. The most common 
      treatment-related adverse events of apatinib were hand-foot syndrome (all grade: 
      39.6%, >/=grade III: 7.5%), hypertension (all grade: 34.5%, >/=grade III: 9.2%), and 
      fatigue (all grade: 28.0%, >/=grade III: 5.1%). Conclusions: In summary, this 
      meta-analysis demonstrated that apatinib has promising efficacy and safety for 
      patients with advanced or recurrent cervical cancer. Systematic Review 
      Registration: https://inplasy.com/inplasy-2022-7-0049/, identifier 
      INPLASY202270049.
CI  - Copyright (c) 2022 Huang, He, Zhai, Shen, Jing, Chen, Zhu and Zhou.
FAU - Huang, Da
AU  - Huang D
AD  - Department of Gynecology, The Second Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - He, Qionghua
AU  - He Q
AD  - Department of Gynecology, The Second Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - Zhai, Lingyun
AU  - Zhai L
AD  - Department of Gynecology, The Second Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - Shen, Jiayu
AU  - Shen J
AD  - Department of Obstetrics, The Second Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - Jing, Fei
AU  - Jing F
AD  - Department of Gynecology, The Second Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - Chen, Huanhuan
AU  - Chen H
AD  - Department of Gynecology, The Second Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - Zhu, Xiaoqing
AU  - Zhu X
AD  - Department of Gynecology, The Second Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - Zhou, Jianwei
AU  - Zhou J
AD  - Department of Gynecology, The Second Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou, China.
LA  - eng
PT  - Systematic Review
DEP - 20220811
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9403417
OTO - NOTNLM
OT  - adverse events
OT  - apatinib
OT  - disease control rate
OT  - objective response rate
OT  - recurrent/metastatic cervical cancer
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/30 06:00
MHDA- 2022/08/30 06:01
PMCR- 2022/08/11
CRDT- 2022/08/29 05:15
PHST- 2021/12/27 00:00 [received]
PHST- 2022/06/22 00:00 [accepted]
PHST- 2022/08/29 05:15 [entrez]
PHST- 2022/08/30 06:00 [pubmed]
PHST- 2022/08/30 06:01 [medline]
PHST- 2022/08/11 00:00 [pmc-release]
AID - 843905 [pii]
AID - 10.3389/fphar.2022.843905 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Aug 11;13:843905. doi: 10.3389/fphar.2022.843905. 
      eCollection 2022.